reports
Genmab Provides Certain Information Disclosed in Connection with Propo...
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab also launched the syndicatio...
Genmab Announces Proposed Private Offering of Senior Secured Notes and...
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab...
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
Genmab Announces Financial Results for the Nine Months of 2025
Genmab Announces Financial Results for the Nine Months of 2025 November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 millionFDA granted BTD to Rina-S® in advanced endometrial cancerEpcoritamab Phase 3 EPCORE® FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and clinically meaningful differences in both endpointsFDA granted priority review of th...
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
Genmab to Participate in a Fireside Chat at the Jefferies Global Healt...
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London Media ReleaseCOPENHAGEN, Denmark; November 5, 2025 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 12:00 PM GMT (7:00 AM EST) on November 19, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppa...
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 ...
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignanciesNew data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EP...
Genmab Commences Tender Offer for All Issued and Outstanding Common Sh...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously...
Genmab Announces New Data Demonstrating Investigational Rinatabart Ses...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometria...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarte...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,...
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Acceleratin...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, ...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2025 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share,...
Major Shareholder Announcement
Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of September 19, 2025, Orbis Investment Management Limited through shares and ADRs, representing shares, controlled the voting rights to 3,230,732 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Invest...
Transactions with shares and linked securities in Genmab A/S made by m...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; September 9, 2025 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 09, 2025 – (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 36,464 shares at DKK 1,025.00,3,978 shares at DKK 1,050.00,497 shares at DKK 1,147.50,267 shares at DKK 1,155.00,691 shares at DKK 1,161.00,439 s...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Eval...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.